
ãã¡ã€ã¶ãŒç€Ÿã®æ©å¯ææžã§ãã³ããã19ã®ã¯ã¯ãã³æ¥çš®ãéçåã«ã€ãªããããšãæããã«
å èšäºã¯ãã¡ããã/Click here to read the original article.
Covid-19ã®ã¯ã¯ãã³æ¥çš®ã倧ééçåãæããšããã
ããã¯ããªã倧èãªäž»åŒµã§ãã
ãããªãã®æ¿åºã¯ããªããæ®ºãããšããŠãããã¯ãã£ãšå€§èã ã
ããããæ®å¿µãªããããããã®å€§èãªäž»åŒµã¯ãä»ãå±±ã®ãããªèšŒæ ã§è£æã¡ãããŠããŸãããã®èšŒæ ã®ã»ãšãã©ã¯ãç±³åœé£åå»è¬åå±ãè£å€æã®åœä»€ã§å
¬è¡šãäœåãªãããããã¡ã€ã¶ãŒç€Ÿã®æ©å¯ææžã«ãããŸãã
ã§ã¯ããŸããã¡ã€ã¶ãŒã®æ©å¯ææžã«å«ãŸãã蚌æ ããèŠãŠãããŸãããã
ç±³åœé£åå»è¬åå±ïŒFDAïŒã¯ã2020幎12æ11æ¥ã«ããã108æ¥éã®å®å šæ§å¯©æ»ã§æ³šå°ãæ¿èªããã«ããããããããã¡ã€ã¶ãŒã®COVID-19ã¯ã¯ãã³ã®å®å šæ§ããŒã¿ã®å ¬éã75幎éé ãããããšããŸããã
ãããã2022幎1æåæ¬ãé£éŠå€äºããŒã¯ã»ããããã³ã¯ãæ¯æ55,000ããŒãžãå ¬éããããåœããã圌ãã¯1ææ«ãŸã§ã«12,000ããŒãžãå ¬éããã
ãã以æ¥ãPHMPTã¯ãã¹ãŠã®ããã¥ã¡ã³ãããŠã§ããµã€ãã«æ²èŒããŠãããææ°ã®æäžã¯ã2022幎6æ1æ¥ã«èµ·ãã£ãã
ããŒã¿ãã³ãã«å«ãŸããææžã®1ã€ã¯ããreissue_5.3.6 postmarketing experience.pdfãã§ãããã®æ©å¯ææžã®12ããŒãžã«ã¯ãåŠåš äžããã³æä¹³äžã®ãã¡ã€ã¶ãŒã³ãã-19泚å°å€ã®äœ¿çšã«é¢ããããŒã¿ãå«ãŸããŠããŸãã
ãã¡ã€ã¶ãŒç€Ÿã®æ©å¯ææžã§ãã³ãããã¯ã¯ãã³æ¥çš®ããåŠå©Šã®9å²ãèµ€ã¡ããã倱ã£ãããšã倿
ãã¡ã€ã¶ãŒã¯ææžã®äžã§ã2021幎2æ28æ¥ãŸã§ã«ãåŠåš äžã«mRNA泚å°ã«æé²ãããæ¢ç¥ã®çäŸã¯270ä»¶ã§ãããšè¿°ã¹ãŠããŸãã
ãã¡ã€ã¶ãŒç€Ÿã®ã³ããã-19泚å°å€ã«æé²ãããæ¯èŠªïŒ124人ïŒã®ãã¡ã46ïŒ ãå¯äœçšã被ã£ãã
ãã®124人ã®ãã¡ã49人ã¯é節ã§ãªãå¯äœçšã§ãã£ããã75人ã¯é節ãªå¯äœçšã§ãã£ããã€ãŸããå¯äœçšã蚎ããæ¯èŠªã®58ïŒ ããåå®®åçž®ããèå æ»äº¡ãŸã§ã®é節ãªå¯äœçšã«èŠèãããããšã«ãªããŸãã

ãã¡ã€ã¶ãŒç€Ÿè£œæ³šå°å€ã®æé²ã«ãããåèš4ä»¶ã®é節ãªèå /ä¹³å ã®çäŸãå ±åãããŸããã

ãããããããããããªãåé¡ã§ãããã¡ã€ã¶ãŒã¯ã270ã®åŠåš ã®ãã¡ã238ã®åŠåš ã§äœãèµ·ãã£ãããŸã£ããããããªããšè¿°ã¹ãŠããŸãã
ããããæ®ãã®åŠåš ã®çµæã«ã€ããŠã¯ã以äžã®éãã§ãã

å ±åæç¹ã§ã¯34ä»¶ã®è»¢åž°ã確èªãããŸãããããã®ãã¡5ä»¶ã¯ãŸã ä¿çãšãªã£ãŠããŸãããã¡ã€ã¶ãŒç€Ÿã«ãããšã29ã®æ¢ç¥ã®çµæã®ãã¡æ£åžžãªãã®ã¯1ã€ã ãã§ããã29ã®çµæã®ãã¡28ã¯èµ€ã¡ããã®æå€±/æ»äº¡ã«ã€ãªãã£ããããã¯ãåŠåš äžã®ã³ããã-19ã¯ã¯ãã³æ¥çš®ã®æ¢ç¥ã®çµæã®97ïŒ ãå ã®æ»äº¡ã«è³ã£ãããšã«çžåœããã
çµæãæªç¢ºå®ã®5ä»¶ãå«ãããšãåŠåš äžã®Covid-19ã¯ã¯ãã³æ¥çš®ã®çµæã®ãã¡ã82ïŒ ããåããŸã®æ»äº¡ã«ã€ãªãã£ãããšã«ãªããŸããã€ãŸãã82ïŒ ãš97ïŒ ã®éã®å¹³åå€ã¯çŽ90ïŒ ãšããããšã«ãªããŸãã
ã€ãŸããåŠåš äžã®ãã¡ã€ã¶ãŒç€Ÿè£œã³ããã19泚å°ã®æäžã«é¢ããŠãäœããééã£ãŠããããšã瀺ãæåã®èšŒæ ãããã«ããã®ã§ãã
è±åœæ¿åºã®ãREG 174 INFORMATION FOR UK HEALTHCARE PROFESSIONALSãææžããåŒçšããã¬ã€ãã³ã¹ã以äžã«ç€ºããŸãã

ãšã«ãã2020幎12æã®ã¬ã€ãã³ã¹ã¯ããèªã¿åããŸãããæ®å¿µãªãããããã1ã¶æã»ã©ã§ãè±åœæ¿åºãã¯ãããšããäžçäžã®æ¿åºã¯ããã®ã¬ã€ãã³ã¹ã以äžã®ããã«æ¹èšããŠããŸããŸããã

ããã¯2022幎6æçŸåšãå ¬åŒã¬ã€ãã³ã¹ã§ããã2021幎åé ããåŠå©Šãã³ããã19ã®ã¯ã¯ãã³æ¥çš®ã¯å®å šã«å®å šã ãšèšãããŠããããšãèãããšãç·æ¥ã«çããªããã°ãªããªãçåãããã€ãåºãŠããŸãã
å®éšçãªæ³šå°ãæã£ãŠãå šãåé¡ãªããšèšãããåã«ãåŠåš äžã«é¿ããããã«èšãããŠããããšãèŠãã°ãäœãããããããšæ°ä»ãã¯ãã ã
éã®ç»è£œã
ãœããããŒãºã
ãŠã§ãããã€ã³ãã
ã³ãŒããŒã
ããŒããã£ãŒã
ãã¿ãã³ãµããªã¡ã³ãã
å å·¥ããããžã£ã³ã¯ããŒã
ãããã¯ã»ãã®äžäŸã§ãæããã°ããããããŸããã
ã§ã¯ãå ¬åŒã¬ã€ãã³ã¹ã®ãåŠåš ãã®é ç®ããèŠãŠãããŸãããã2020幎12æã®ã¬ã€ãã³ã¹ã§ã¯ãåŠåš äžã®ã³ãã19ã¯ã¯ãã³æ¥çš®ã¯æšå¥šãããªãããšèšèŒãããŠããŸãããã®ããã1ã«æã»ã©åŸã«ããã®ã¬ã€ãã³ã¹ã¯ãåç©å®éšã§ã¯åŠåš ãªã©ã«é¢ããŠæå®³ãªåœ±é¿ã瀺ãããšã¯ãªãããšè¿°ã¹ãŠããŸãã
ã§ã¯ãåé¡ã®åç©å®éšãèŠãŠã¿ãŸãããã
ãããããã®åã«ã2022幎6æçŸåšãå ¬åŒã¬ã€ãã³ã¹ã§ã¯ããåŠåš äžã®COVID-19 mRNAã¯ã¯ãã³BNT162b2ã®æäžã¯ãæ¯äœåã³èå ã«å¯Ÿããæœåšçãªãªã¹ã¯ãäžåãå©çãããå Žåã«ã®ã¿èæ ®ãããã¹ãã§ããããšãããŠããããšãææããŠããå¿ èŠããããŸããã§ã¯ãäžäœãªããäžçäžã®åŠå©Šããã®æ³šå°ãåããããã«ç©æ¥µçã«åŒ·èŠãããŠããã®ã§ããããïŒ
ãã¡ã€ã¶ãŒãšèŠå¶åœå±ããåŠåš äžã®ã³ãã19ã¯ã¯ãã³æ¥çš®ã®å±éºæ§ãé ããŠããããšã倿ã
å ¬åŒã¬ã€ãã³ã¹ã§èªãããéå®çãªåç©å®éšã§ã¯ãçºè²äžã®èå ã«é倧ãªå®³ãåãŒããªã¹ã¯ãå®éã«çºèŠãããŸããããç±³åœãè±åœããªãŒã¹ãã©ãªã¢ã®å»è¬åèŠå¶åœå±ã¯ããã®æ å ±ãå ¬çææžããåé€ããããšãç©æ¥µçã«éžæããŸããã
å®éã®ç ç©¶ã¯ãããã§å šæãèŠãããšãã§ããã¿ã€ãã«ã¯ãmRNAããŒã¹ã®COVID-19ã¯ã¯ãã³ã§ããBNT162b2ã«ããã©ããã®éã®çæ®èœåããã³åºçåãšåºçåŸã®åå«ã®çºéãžã®åœ±é¿ã®æ¬ åŠãã§ããã
ãã®ç ç©¶ã¯ãéã®Wistar Hanã©ãã42å¹ã察象ã«è¡ãããŸããã21å¹ã«ãã¡ã€ã¶ãŒç€Ÿã®Covid-19泚å°ãè¡ãã21å¹ã«ã¯è¡ããªãã£ãã
以äžã¯ããã®è©Šéšçµæã§ãã

å¯Ÿç §çŸ€ã§ã¯ãè °è骚ã®äžä¹ãã芳å¯ãããèå ã®æ°ã¯3/3ïŒ2.1ïŒã§ãã£ããããããã¯ã¯ãã³æ¥çš®çŸ€ã§ã¯ãè °èéªšè¶ æ°å€ã®èå æ°ã¯6/12ïŒ8.3ïŒã§ãã£ãããããã£ãŠãå¹³åãããšãã¯ã¯ãã³æ¥çš®çŸ€ã§ã¯çºççã295ïŒ é«ããªã£ãããšã«ãªããŸãã
å¯è骚ãšãåŒã°ããè骚ã¯ãé æ€ãè °æ€ããçºçããããšãå€ããçããè骚ã®äœå°çš®ã§ããã
ã€ãŸãããã®ç ç©¶ã§èŠã€ãã£ãã®ã¯ããã¡ã€ã¶ãŒç€Ÿã®ã³ããã19泚å°ã«ããèå ã®ç°åžžåœ¢æãšåºçç°åžžã®èšŒæ ãªã®ã§ãã
ãããããã®ç ç©¶ã®ç°åžžãªæèŠã¯ããã ãã«ãšã©ãŸããŸãããã¯ã¯ãã³æ¥çš®ãåããã©ããã®ãçåºåæå€±ãçã¯ãå¯Ÿç §çŸ€ã®2åã§ãã£ãã

çåºåæå€±ãšã¯ãå粟åµãçåºããªãããšãæããŸãããããã£ãŠããã®ç ç©¶ã¯ããã¡ã€ã¶ãŒç€Ÿã®ã³ããã-19泚å°ãã女æ§ãåŠåš ã§ããå¯èœæ§ãäœäžãããããšã瀺åããŠããŸããã€ãŸããäžåŠçã®ãªã¹ã¯ãé«ãããšããããšã§ãã
ã§ã¯ããã£ããã©ããã£ãŠäžçäžã®è¬äºèŠå¶åœå±ãå ¬åŒã¬ã€ãã³ã¹ã§ãåç©å®éšã§ã¯ãåŠåš ã«é¢ããçŽæ¥çãŸãã¯éæ¥çãªæå®³äœçšã¯ç€ºãããŠããªãããšè¿°ã¹ãããšãã§ããã®ã§ããããããŸããããã¡ã€ã¶ãŒç€Ÿã®ã¯ã¯ãã³ãçæ®èœåã«åœ±é¿ãäžãããã©ããã¯äžæã§ãããšãè¿°ã¹ãŠããã®ã§ããããïŒ
ãã®åé¡ã®ççžã¯ã圌ããç©æ¥µçã«é èœããããšãéžãã ãšããããšã§ãã
ç§ãã¡ã¯ããªãŒã¹ãã©ãªã¢æ¿åºä¿å¥çæ²»ççšå管çå±ïŒTGAïŒã«å¯ŸããŠè¡ã£ããæ å ±å ¬éè«æ±ïŒFOIïŒãã®ãããã§ããã®ããšãç¥ã£ãŠããŸãã
2021幎1æ11æ¥ã«äœæããããDelegate's Overview and Request for ACV's Adviceããšé¡ãããææžããFOIãªã¯ãšã¹ãã®ããšå ¬éãããŸãããææžã®30ããŒãžä»¥éã«ã¯ããè£œåæ å ±ã®èŠçŽããã瀺ãããŠãããæ£åŒãªåºçã«å ç«ã£ãŠãéèšåºè©äŸ¡å ±åæžãã«å ããããã¹ã倿Žã匷調ãããŠããã
ãã®å€æŽã¯ã次ã®è£œåæ å ±æŽæ°ã®åã«ãã¡ã€ã¶ãŒãè¡ãããèŠè«ããããã®ã§ãã
ãããã®èŠæ±ããã倿Žã®äžéšã¯ã以äžã®éãã§ãã£ã-ã

ã¢ãžã¥ãŒã« 4 ã®è©äŸ¡è ã¯ããã¡ã€ã¶ãŒã«å¯Ÿãããåç©å®éšã§ã¯ãçæ®æ¯æ§ã«é¢ããŠçŽæ¥çãŸãã¯éæ¥çãªæå®³äœçšã¯ç€ºãããŠããªãããšãã䞻匵ãåé€ããããèŠè«ããŸããã
ãªãã§ããïŒ

ã¢ãžã¥ãŒã«4ã®è©äŸ¡è ã¯ããã¡ã€ã¶ãŒç€Ÿã«ãåŠåš ã«ããŽãªãŒB2ããé©åã§ãããšèãã以äžã®è¡ã远å ããããèŠè«ããŸããã
ãã©ãããçšããåèèœãšçºçæ¯æ§ã®è€å詊éšã§ãCOMIRNATYãæäžããéã©ããã®èå ã«è °æ€è骚ã®è¶ æ°å€ã®çºçãå¢å ãã ããšãããŸãã
ããããããã§äžè¬åãã«çºè¡ãããå ¬ææžã®èªã¿æ¹ãæãåºããŠã¿ãŠãã ãã--ã

åŠåš ã«ããŽãªãŒããB1ãã«å€æŽãããèå ã®è °è骚ã®è¶ æ°å€ã®çºççã®å¢å ã«é¢ããè¡ã¯å«ãŸããã代ããã«ãåç©å®éšã§ã¯ãåŠåš ã«é¢ããŠçŽæ¥çãŸãã¯éæ¥çãªæå®³äœçšã¯ç€ºãããŠããªãã»ã»ã»ããšäž»åŒµããåé€èŠè«ã®ãã£ãè¡ãå«ãŸããããšã«ãªã£ãã®ã§ãã
以äžã¯ãåŠåš ã«ããŽãªãŒã«ã€ããŠã®å ¬åŒãªèª¬æã§ãã

ãã®2ã€ã®ã«ããŽãªãŒã«ã¯ãããªã倧ããªå·®ããããŸãããããããã¢ãžã¥ãŒã«4ã®è©äŸ¡è ãåŠåš åé¡B2ãé©åã ãšèãããšããäºå®ã¯ãäžèšã§æããã«ããããã«ããã¡ã€ã¶ãŒç€Ÿã®ã³ããã19泚å°ãåŠåš äžã«æäžããããšã®å®å šæ§ãè©äŸ¡ããããã«è¡ããããäžååãã§æ¥µããŠå°èŠæš¡ãªåç©å®éšã®çµæãèæ ®ãããšãéåžžã«çåãæ®ãã
ã€ãŸãããã¡ã€ã¶ãŒç€Ÿã®ã¯ã¯ãã³ã¯ãæ¥çš®è ã®82ïŒ ãã97ïŒ ãèµ€ã¡ããã倱ãå¯èœæ§ããããšãã蚌æ ãããã ãã§ãªãããã¡ã€ã¶ãŒç€Ÿã®ã¯ã¯ãã³ã¯ãäžåŠçãå å€©æ§æ¬ æçã«ããããªã¹ã¯ã®äžæã«ã€ãªãããšãã蚌æ ãããã®ã§ãã
ãã®2ã€ã®äŸã ãã§ããã³ããã19ã®ã¯ã¯ãã³æ¥çš®ãéçåã«ã€ãªãããšããææãæ¯æããããšãã§ããŸããããããæ®å¿µãªããã蚌æ ã¯ããã ãã«ãšã©ãŸããŸããã
ãã¡ã€ã¶ãŒç€Ÿã®æ©å¯ææžã§ãã³ããã19ã¯ã¯ãã³ãåµå·£ã«èç©ãããããšã倿
FDAãè£å€æåœä»€ã«ãã£ãŠå ¬éãäœåãªãããããã¡ã€ã¶ãŒç€Ÿã®æ©å¯ææžã®é·ããªã¹ãã«æ²èŒãããŠããå¥ã®ç ç©¶ã¯ããŠã£ã¹ã¿ãŒã»ãã³ã©ããïŒ21å¹ãéã21å¹ãéïŒã§å®æœããããã®ã§ããã
åã©ããã¯ããã¡ã€ã¶ãŒç€Ÿã®ã³ããã19泚å°å€ãçèå ã«1åæäžãããæäžåŸãããããå®ããããæç¹ã§ãè¡æ¶²ãè¡æŒ¿ãçµç¹äžã®ç·æŸå°èœã®å«æéãšæ¿åºŠã枬å®ãããŸããã
ã€ãŸãããã®ç ç©¶ã§ã¯ãã³ããã19泚å°è¬ãç®èãèèãèŸèãå¿èãªã©äœã®ä»ã®éšåã«ã©ãã ãåºãã£ãŠããããæž¬å®ããã®ã§ããã
ãããããã®ç ç©¶ã§æãæ°ã«ãªãçµæã®ã²ãšã€ã¯ããã¡ã€ã¶ãŒç€Ÿã®æ³šå°å€ãæéãšãšãã«åµå·£ã«èç©ããããšããäºå®ã§ãã
åµå·£ããšã¯ãåµåã圢æããã女æ§ãã«ã¢ã³ã®ãšã¹ããã²ã³ãšããã²ã¹ããã³ãäœãããäžå¯Ÿã®å¥³æ§è ºã®ãã¡ã®1ã€ã§ãã

ãã¡ã€ã¶ãŒç€Ÿè£œãžã£ããæ³šå°ããŠããæåã®15åéã§ãåµå·£å ã®ç·è質æ¿åºŠã0.104mlãšãªã£ãããšãåãããŸããããã®åŸã1æéåŸã«ã¯1.34mlã4æéåŸã«ã¯2.34mlããããŠ48æéåŸã«ã¯12.3mlã«å¢å ããã
ããããç§åŠè ãã¡ã¯ã48æéåŸã®èç©ã«ã€ããŠãã以äžã®èª¿æ»ãè¡ã£ãŠããªãããããã®èç©ãç¶ããŠãããã©ããã¯ããããªãã
ããããã¹ã³ããã©ã³ãå ¬è¡è¡çå±ãçºè¡šããè±åœã®å ¬åŒããŒã¿ã¯ãåµå·£ã«èç©ãããçµæã«ã€ããŠãããã€ãã®è峿·±ãæããããäžããŠãããŸãã
åµå·£ããã«çœ¹æ£ããŠããåäººã®æ°ã®æ°å€ã¯ã2021å¹Žã®æ¢ç¥ã®åŸåãã2020幎ããã³2017幎ãã2019幎ã®å¹³åãããå€§å¹ ã«é«ãããšã瀺ããŠããŸãã

äžèšã®ã°ã©ãã¯2021幎6æãŸã§ã®ãã®ã§ãããã¹ã³ããã©ã³ãå ¬è¡è¡çå±ã®ããã·ã¥ããŒãã«ãããã£ãŒãã§ã¯2021幎12æãŸã§ã®æ°åã衚瀺ãããããã«ãªããæ®å¿µãªããåµå·£ããã«ããã女æ§ã®æ°ãå€§å¹ ã«å¢ãããã®å·®ãããã«åºãã£ãŠããããšãæããã«ãªããŸããã

ããã§ã3ã€ç®ã®èšŒæ ã¯çµããã§ããããã§ãç§ãã¡ã¯ç¥ã£ãŠãã-ã
ãã¡ã€ã¶ãŒã®æ©å¯ææžã«ã¯ã82ïœ97ïŒ ã®æµç£çãèšãããŠããŸãã
åŠåš äžã®ãã¡ã€ã¶ãŒç€Ÿè£œã¯ã¯ãã³æäžã®å®å šæ§ã蚌æããããã«è¡ãããå¯äžã®åç©å®éšã§ã¯ãäžåŠçãå 倩æ§ç°åžžã®ãªã¹ã¯ãå¢å ããããšãææãããŠããŸãã
ãšãããã«ãã¡ã€ã¶ãŒç€Ÿã®æ©å¯ææžãããã¯ã¯ãã³ãåµå·£ã«èç©ãããããšã倿ããŸããã
æ®å¿µãªãããã³ããã19ã®ã¯ã¯ãã³æ¥çš®ã«ãã£ãŠæ°çå ãæ²ããããšã«åœãèœãšããªã¹ã¯ãé«ãŸããšãã蚌æ ããããããã¯ã¹ã³ããã©ã³ãå ¬è¡è¡çå±ã®ãã³ããã19 Wider Impactsãããã·ã¥ããŒããããåŸãããŠããã®ã§ãã
2022幎3æãæ°çå ã®æ»äº¡æ°ã7ã«æã¶ã2床ç®ã®å±æ©çæ°Žæºã«
å ¬åŒçºè¡šã«ãããšã2022幎3æã®æ°çå æ»äº¡çã¯åºç1000人ããã4.6人ãšãªããäºæ³æ»äº¡çã«å¯ŸããŠ119ïŒ å¢å ããããšãæããã«ãªããŸãããããã¯ãæ°çå æ»äº¡çãå°ãªããšã4幎ã¶ãã«2床ç®ãã管çéçããšããŠç¥ãããèŠåã®äžéå€ãçªç Žããããšãæå³ããŸãã
ååçªç Žããã®ã¯2021幎9æã§ããã®ãšãã¯åºç1000人ãããã®æ°çå æ»äº¡æ°ã5.1人ã«ãŸã§äžæãããæã«ãã£ãŠå€åã¯ãããã®ã®ã2021幎9æãš2022幎3æã®æ°å€ã¯ã1980幎代åŸåã«å žåçã«èŠãããæåŸã®æ°Žæºã«å¹æµãããã®ã§ããã

ã¹ã³ããã©ã³ãå ¬è¡è¡çå±ïŒPHSïŒã¯èª¿æ»ãéå§ããããšãæ£åŒã«çºè¡šããªãã£ãããããã¯èŠåã®äžéå€ã«éãããšãã«è¡ãããšã«ãªã£ãŠããã2021幎ã«ããããŠããã
åœæPHSã¯ã管çäžéå€ãè¶ ãããšããäºå®ã¯ããçºçããæ»äº¡è æ°ã«ã©ã³ãã ãªå€å以äžã®èŠå ãããå¯èœæ§ãé«ãããšã瀺ããŠããããšè¿°ã¹ãŠããŸãã
Covid-19ã®ã¯ã¯ãã³æ¥çš®ãéçåã«ã€ãªãããšãã䞻匵ãè£ä»ããæåŸã®èšŒæ ã¯ãããçŸå®çãªããŒã¿ãšãã圢ã§ãä»åºŠã¯ã¢ã¡ãªã«ãããããããããã®ã§ããã
Covid-19ã¯ã¯ãã³æ¥çš®ã«ãããæµç£ã«èŠèããããªã¹ã¯ãå°ãªããšã1,517%å¢å ããã
ç±³åœçŸç 管çã»ã³ã¿ãŒïŒCDCïŒã®çºè¡šã«ãããš) ã¯ã¯ãã³æå®³äºè±¡ããŒã¿ããŒã¹ïŒVAERSïŒã§ã¯ã2022幎4æçŸåšãã³ããã19泚å°ã«å¯Ÿããå¯äœçšãšããŠãåèš4,113ä»¶ã®èå æ»äº¡ãå ±åãããŠããããã®ãã¡3,209ä»¶ã¯ãã¡ã€ã¶ãŒæ³šå°ã«å¯ŸããŠå ±åãããŠããŸãã

CDCã¯ãVAERSã«å®éã«å ±åãããå¯äœçšã¯ããã1ïœ10ïŒ ã§ããããšãèªããŠãããããæ¬åœã®æ°åã¯äœåãæªããªãå¯èœæ§ããããŸãããããããã®æ°åãèæ ®ãããšã2020幎12æã«ã³ããã-19泚å°ã®ç·æ¥äœ¿çšèš±å¯ãäžããåã®30幎éã§ãVAERSã«å ±åãããèå æ»äº¡ã¯2,239ä»¶ãããªãã£ãããšã«ãªããŸãã(åºå ž)
ããã«ãã³ããã19ã®ã¯ã¯ãã³æ¥çš®åŸã«æµç£ãããªã¹ã¯ã¯ãã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³æ¥çš®åŸã«æµç£ãããªã¹ã¯ããã1,517ïŒ é«ããšããç ç©¶çµæãçºè¡šãããŸããïŒãã¡ããã芧ãã ããïŒã

ããããåŠå©Šã¯ã€ã³ãã«ãšã³ã¶ã®äºé²æ¥çš®ã®å¯Ÿè±¡ã§ãããã³ããã19ã®äºé²æ¥çš®ã®å¯Ÿè±¡ãšããŠã¯å°æ°æŽŸã§ãããããæ¬åœã®ãªã¹ã¯ã¯ãã£ãšé«ããããããŸããã
ãšãã»ã€ã«ãªãã®ãèŠæã§ã仿¥ã®ãšããã³ã¹ã¯ããã§çµããã§ããããŸã ãŸã ããããããã®ã§ãå¿ ãå ±åããŸãã
ãããã
æµç£çã82ïŒ ãã97ïŒ ã§ããããšã瀺ããã¡ã€ã¶ãŒç€Ÿã®æ©å¯ææžã
åŠåš äžã«ãã¡ã€ã¶ãŒç€Ÿã®ã¯ã¯ãã³ãæäžããå Žåã®å®å šæ§ã蚌æããããã«è¡ãããå¯äžã®åç©å®éšã§ã¯ãäžåŠçãå 倩æ§ç°åžžã®ãªã¹ã¯ãå¢å ããããšã瀺ãããŠããŸãã
ããã«ããã¡ã€ã¶ãŒç€Ÿã®æ©å¯ææžã«ãããã¯ã¯ãã³ãåµå·£ã«èç©ãããããšãæããã«ãªããã¹ã³ããã©ã³ãã®ããŒã¿ã§ã¯ãåµå·£çã®çäŸãé廿é«ã§ããããšã倿ããŸããã
ã¹ã³ããã©ã³ãã§ã¯ãæ°çå ã®æ»äº¡æ°ããã®7ã¶æã§2åç®ãšãªã屿©çãªæ°Žæºã«éããŠããããšãæããã«ãªããŸããã
ãšCDCã®VAERSããŒã¿ã«ãããšãCovid-19ã®ã¯ã¯ãã³æ¥çš®ã¯æµç£ã«èŠèããããªã¹ã¯ãå°ãªããšã1,517ïŒ å¢å ãããããšã瀺ãããŠããŸãã
ã³ãã19ã®ã¯ã¯ãã³æ¥çš®ãéçåã«ã€ãªãããšãã䞻匵ã«ã¯ããã§ã«ååãããã»ã©ã®æ ¹æ ãããããã§ãã